Edge Wealth Management LLC Iovance Biotherapeutics, Inc. Transaction History

Edge Wealth Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 21, 2020	SELL	$27.75 - $36.3 $253,746 - $331,927	-9,144 Closed	0 $0
Q2 2020 Aug 03, 2020	SELL	$27.21 - $41.0 $544 - $820	-20 Reduced 0.22%	9,144 $251,000
Q1 2020 Apr 20, 2020	BUY	$19.54 - $38.85 $977 - $1,942	50 Added 0.55%	9,164 $271,000
Q4 2019 Jan 29, 2020	BUY	$17.95 - $29.41 $12,565 - $20,587	700 Added 8.32%	9,114 $252,000
Q2 2019 Jul 15, 2019	BUY	$9.78 - $24.52 $13,828 - $34,671	1,414 Added 20.2%	8,414 $207,000
Q1 2019 Apr 11, 2019	BUY	$8.41 - $11.26 $4,205 - $5,630	500 Added 7.69%	7,000 $67,000
Q4 2018 Jan 11, 2019	SELL	$7.51 - $11.93 $1,502 - $2,386	-200 Reduced 2.99%	6,500 $58,000
Q3 2018 Oct 22, 2018	SELL	$11.25 - $17.7 $19,687 - $30,975	-1,750 Reduced 20.71%	6,700 $75,000
Q2 2018 Jul 17, 2018	SELL	$12.45 - $16.95 $17,118 - $23,306	-1,375 Reduced 13.99%	8,450 $108,000
Q1 2018 Apr 05, 2018	SELL	$8.1 - $19.5 $68,752 - $165,516	-8,488 Reduced 46.35%	9,825 $166,000
Q4 2017 Jan 18, 2018	SELL	$6.65 - $9.25 $6,650 - $9,250	-1,000 Reduced 5.18%	18,313 $145,000
Q3 2017 Oct 19, 2017	BUY	$4.45 - $8.55 $85,942 - $165,126	19,313	19,313 $150,000

297

234M

1.14M

1.15M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $308M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Edge Wealth Management LLC, based on Form 13F filings with the SEC.

Stay updated on Edge Wealth Management LLC with notifications on news.